"le\\\" colspan=\\\"5\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.3</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.8 (-1.0, -0.7)<span class=\\\"Sup\\\">‡‡</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.1 (-1.2, -0.9)<span class=\\\"Sup\\\">‡‡</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from exenatide<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.3 (-0.4, -0.2)<span class=\\\"Sup\\\">††</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.5 (-0.7, -0.4)<span class=\\\"Sup\\\">††</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Percentage of patients HbA1c &lt;7.0%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">43</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">66**<span class=\\\"Sup\\\">, ##</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">78**<span class=\\\"Sup\\\">, ##</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">52</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">166</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">159</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">162</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">164</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-34</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-42</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-24</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-30 (-36, -23)</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-38 (-45, -31)</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from exenatide<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-10 (-15, -5)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-18 (-24, -13)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">94.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">95.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">96.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">97.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">1.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">0.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.3</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.0 (-1.8, -0.3)</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-2.5 (-3.3, -1.8)</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from exenatide<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.3 (0.6, 1.9)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.2 (-0.9, 0.4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr></tbody></table><div class=\\\"Figure\\\"><a name=\\\"f05\\\"></a><img alt=\\\"Figure 5\\n\\\" src=\\\"trulicity-pi-f5-v2.jpg\\\"/></div><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"19.175%\\\"/><col align=\\\"left\\\" width=\\\"18.350%\\\"/><col align=\\\"left\\\" width=\\\"33.350%\\\"/><col align=\\\"left\\\" width=\\\"29.125%\\\"/><tfoot><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Mean HbA1c adjusted for baseline HbA1c and country.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of patients with observed data</span></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">Placebo</td><td align=\\\"center\\\" valign=\\\"top\\\">141</td><td align=\\\"center\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"top\\\">108</td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">TRULICITY 0.75 mg</td><td align=\\\"center\\\" valign=\\\"top\\\">280</td><td align=\\\"center\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"top\\\">251</td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">TRULICITY 1.5 mg</td><td align=\\\"center\\\" valign=\\\"top\\\">279</td><td align=\\\"center\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"top\\\">259</td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">Exenatide</td><td align=\\\"center\\\" valign=\\\"top\\\">276</td><td align=\\\"center\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"top\\\">242</td></tr></tbody></table><p class=\\\"MultiMediaCaption\\\"><span class=\\\"Bold\\\">Figure 5: Adjusted Mean HbA1c at Each Time Point (ITT, MMRM) and at Week 26 (ITT, LOCF)</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s84\\\"></a><a name=\\\"section-13.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Placebo-Controlled Trial (Add-on to SGLT2i, with or without Metformin)</span></p><p>In this 24-week placebo-controlled, double-blind trial, 423 adult patients were randomized to and received TRULICITY 0.75 mg, TRULICITY 1.5 mg, or placebo, as add-on to sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy (96% with and 4% without metformin). Trulicity was administered once weekly, and SGLT2i was administered according to the local country label. Patients had a mean age of 57 years; mean duration of type 2 diabetes of 9.4 years; 50% were male; race: White, Black, and Asian were 89%, 3%, and 0.2%, respectively; and 21% of the trial population was in the US.</p><p>At 24 weeks, treatment with once weekly TRULICITY 0.75 mg and 1.5 mg resulted in a statistically significant reduction from baseline in HbA1c compared to placebo (<a href=\\\"#t9\\\">Table 9</a>).</p><p>The mean baseline body weight was 90.5, 91.1, and 92.9 kg in the placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg groups, respectively. The mean changes from baseline in body weight at Week 24 were -2.0, -2.5, and -2.9 kg for placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, respectively. The difference from placebo (95% CI) was -0.9 kg (-1.7, -0.1) for TRULICITY 1.5 mg.</p><a name=\\\"t9\\\"></a><table width=\\\"100%\\\"><caption><span>Table 9: Results at Week 24 of TRULICITY as Add-on to SGLT2i in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"35.666%\\\"/><col align=\\\"left\\\" width=\\\"21.445%\\\"/><col align=\\\"left\\\" width=\\\"21.445%\\\"/><col align=\\\"left\\\" width=\\\"21.445%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: HbA1c = hemoglobin A1c; SGLT2i = sodium-glucose co-transporter-2 inhibitors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. At Week 24, primary efficacy was missing for 3%, 4%, and 6% of individuals treated with placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean adjusted for baseline value and other stratification factors. Placebo multiple imputation, using baseline and 24-week values from the placebo arm, was applied to model a washout of the treatment effect for patients missing 24-week values (HbA1c, fasting serum glucose, and body weight).</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Patients with missing HbA1c data at Week 24 were considered as non-responders.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">††</span> p&lt;0.001 for superiority of TRULICITY compared to placebo, overall type I error controlled.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"bottom\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">24-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY <br/>0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY <br/>1.5 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">140</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">141</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">142</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.7 (-0.8, -0.5)<span class=\\\"Sup\\\">††</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.8 (-0.9, -0.6)<span class=\\\"Sup\\\">††</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Percentage of patients HbA1c &lt;7.0%</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">31</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">59<span class=\\\"Sup\\\">††</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">67<span class=\\\"Sup\\\">††</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">153</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">162</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">161</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-25</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-30</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-19 (-25, -13)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-24 (-30, -18)<span class=\\\"Sup\\\">††</span></td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s85\\\"></a><a name=\\\"section-13.3.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Insulin Glargine Controlled Trial (Add-on to Metformin and Sulfonylurea)</span></p><p>In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 52 weeks, 807 adult patients were randomized to and received TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all as add-on to maximally tolerated doses of metformin and glimepiride. Randomization occurred after a 10-week lead-in period; during the initial 2 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and glimepiride. This was followed by a 6- to 8-week glycemic stabilization period prior to randomization.</p><p>Patients randomized to insulin glargine were started on a dose of 10 units once daily. Insulin glargine dose adjustments occurred twice weekly for the first 4 weeks of treatment based on self-measured fasting plasma glucose (FPG), followed by once weekly titration through Week 8 of treatment, utilizing an algorithm that targeted a fasting plasma glucose of &lt;100 mg/dL. Only 24% of patients were titrated to goal at the 52-week primary endpoint. The dose of glimepiride could be reduced or discontinued after randomization (at the discretion of the investigator) in the event of persistent hypoglycemia. The dose of glimepiride was reduced or discontinued in 28%, 32%, and 29% of patients randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine.</p><p>Patients had a mean age of 57 years; mean duration of type 2 diabetes of 9 years; 51% were male; race: White, Black and Asian were 71%, 1% and 17%, respectively; and 0% of the trial population were in the US.</p><p>Treatment with TRULICITY once weekly resulted in a reduction in HbA1c from baseline at 52 weeks when used in combination with metformin and sulfonylurea (<a href=\\\"#t10\\\">Table 10</a>). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%.</p><a name=\\\"t10\\\"></a><table width=\\\"100%\\\"><caption><span>Table 10: Results at Week 52 of TRULICITY Compared to Insulin Glargine, Both as Add-on to Metformin and Sulfonylurea in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"35.725%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 52, primary efficacy was missing for 17%, 13% and 12% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and glargine, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">‡</span> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 267, 263 and 259 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine, respectively.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"bottom\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">52-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY <br/>0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY <br/>1.5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Insulin Glargine</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">‡</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">272</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">273</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">262</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">161</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">165</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">163</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-16</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-27</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-32</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from insulin glargine<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">16 (9, 23)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">5 (-2, 12)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">86.4</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">85.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">87.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.3</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.9</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">1.4</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from insulin<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-2.8 (-3.4, -2.2)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-3.3 (-3.9, -2.7)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s86\\\"></a><a name=\\\"section-13.3.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Placebo-Controlled Trial (Add-on to Basal Insulin, with or without Metformin)</span></p><p>In this 28-week placebo-controlled, double-blind trial, 300 adult patients were randomized to placebo or once weekly TRULICITY 1.5 mg, as add-on to titrated basal insulin glargine (with or without metformin). Patients had a mean age of 60 years; mean duration of type 2 diabetes of 13 years; 58% were male; race: White, Black, and Asian were 94%, 4%, and 0.3%, respectively; and 20% of the trial population was in the US.</p><p>The mean starting dose of insulin glargine was 37 units/day for patients receiving placebo and 41 units/day for patients receiving TRULICITY 1.5 mg. At randomization, the initial insulin glargine dose in patients with HbA1c &lt;8.0% was reduced by 20%.</p><p>At 28 weeks, treatment with once weekly TRULICITY 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo (<a href=\\\"#t11\\\">Table 11</a>).</p><a name=\\\"t11\\\"></a><table width=\\\"100%\\\"><caption><span>Table 11: Results at Week 28 of TRULICITY Compared to Placebo as Add-On to Basal Insulin in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"35.833%\\\"/><col align=\\\"left\\\" width=\\\"32.533%\\\"/><col align=\\\"left\\\" width=\\\"31.633%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. At Week 28, primary efficacy was missing for 12% and 8% of individuals randomized to placebo and TRULICITY 1.5 mg, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. Placebo multiple imputation, with respect to baseline values, was used to model a wash-out of the treatment effect for patients having missing Week 28 data.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Patients with missing HbA1c data at Week 28 were considered as non-responders.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">††</span> p&lt;0.001 for superiority of TRULICITY 1.5 mg compared to placebo, overall type I error controlled.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">†</span> p≤0.005 for superiority of TRULICITY 1.5 mg compared to placebo, overall type I error controlled.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"bottom\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">28-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">TRULICITY<br/>1.5 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">150</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">150</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.3</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.7</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.7 (-0.9, -0.5)<span class=\\\"Sup\\\">††</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Percentage of patients HbA1c &lt;7.0%</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">33</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">67<span class=\\\"Sup\\\">††</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">156</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">157</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-30</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-44</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-14 (-23, -4)<span class=\\\"Sup\\\">†</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">92.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">93.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">0.8</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.3</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-2.1 (-2.9, -1.4)<span class=\\\"Sup\\\">††</span></td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s87\\\"></a><a name=\\\"section-13.3.8\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Insulin Glargine-Controlled Trial (Combination with Prandial Insulin, with or without</span><span class=\\\"Underline\\\">Metformin)</span></p><p>In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, 884 adult patients on 1 or 2 insulin injections per day were enrolled. Randomization occurred after a 9-week lead-in period; during the initial 2 weeks of the lead-in period, patients continued their pre-trial insulin regimen but could be initiated and/or up-titrated on metformin, based on investigator discretion; this was followed by a 7-week glycemic stabilization period prior to randomization.</p><p>At randomization, patients discontinued their pre-trial insulin regimen and were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro 3 times daily, with or without metformin. Insulin lispro was titrated in each arm based on preprandial and bedtime glucose, and insulin glargine was titrated to a fasting plasma glucose goal of &lt;100 mg/dL. Only 36% of patients randomized to glargine were titrated to the fasting glucose goal at the 26-week primary timepoint.</p><p>Patients had a mean age of 59 years; mean duration of type 2 diabetes of 13 years; 54% were male; race: White, Black and Asian were 79%, 10% and 4%, respectively; and 33% of the trial population were in the US.</p><p>Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a reduction in HbA1c from baseline. The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4% (<a href=\\\"#t12\\\">Table 12</a>).</p><a name=\\\"t12\\\"></a><table width=\\\"100%\\\"><caption><span>Table 12: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"36.675%\\\"/><col align=\\\"left\\\" width=\\\"20.475%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviation: HbA1c = hemoglobin A1c</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 14%, 15%, and 14% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and glargine, respectively.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">‡</span> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 275, 273 and 276 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine, respectively.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"bottom\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">26-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">TRULICITY<br/>0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY<br/>1.5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Insulin Glargine</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat (ITT) Population (N)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">‡</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">293</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">295</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">296</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.4</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.5</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-1.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">150</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">157</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">154</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">4</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-5</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-28</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from insulin glargine<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">32 (24, 41)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">24 (15, 32)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Body Weight (kg) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">91.7</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">91.0</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">90.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">0.2</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.9</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">2.3</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from insulin glargine<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-2.2 (-2.8, -1.5)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-3.2 (-3.8, -2.6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-</td></tr></tbody></table></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s88\\\"></a><a name=\\\"section-13.4\\\"></a><p></p><h2>14.4 Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus and Moderate to Severe Chronic Kidney Disease</h2><p class=\\\"First\\\">In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, a total of 576 adult patients with type 2 diabetes were randomized and treated to compare TRULICITY 0.75 mg and 1.5 mg with insulin glargine (NCT01621178).</p><p>Patients on insulin and other antidiabetic therapy (e.g., oral antidiabetic drugs, pramlintide) had non-insulin therapies discontinued and had their insulin dose adjusted for 12 weeks prior to randomization. Patients on insulin therapy alone maintained a stable insulin dose for 3 weeks prior to randomization. At randomization, patients discontinued their pre-trial insulin regimen and patients were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro. For patients randomized to insulin glargine, the initial insulin glargine dose was based on the basal insulin dose prior to randomization. Insulin glargine was allowed to be titrated with a fasting plasma glucose goal of ≤150 mg/dL. Insulin lispro was allowed to be titrated with a preprandial and bedtime glucose goal of ≤180 mg/dL.</p><p>Patients had a mean age of 65 years; a mean duration of type 2 diabetes of 18 years; 52% were male; race: White, Black, and Asian were 69%, 16%, and 3%, respectively; and 32% of the trial population were in the US. At baseline, overall mean eGFR was 38 mL/min/1.73 m<span class=\\\"Sup\\\">2</span>, 30% of patients had eGFR &lt;30 mL/min/1.73 m<span class=\\\"Sup\\\">2</span>, and 45% of patients had macroalbuminuria. Patients on over 70 units/day of basal insulin were excluded from the trial.</p><p>Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a reduction in HbA1c at 26-weeks from baseline. The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%. Mean fasting plasma glucose increased in the TRULICITY arms (<a href=\\\"#t13\\\">Table 13</a>).</p><p>Mean baseline body weight was 90.9 kg, 88.1 kg, and 88.2 kg in the TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine arms, respectively. The mean changes from baseline at Week 26 were -1.1, -2, and 1.9 kg in the TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine arms, respectively.</p><a name=\\\"t13\\\"></a><table width=\\\"100%\\\"><caption><span>Table 13: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro, in Patients with Moderate to Severe Chronic Kidney Disease in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"36.675%\\\"/><col align=\\\"left\\\" width=\\\"20.475%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviation: HbA1c = hemoglobin A1c</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Intent-to-treat population (all randomized and treated patients) was used in the analysis regardless of discontinuation of study drug or initiation of rescue therapy. At Week 26, primary efficacy was missing for 12%, 15%, and 9% of individuals randomized to and treated with TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine, respectively. Missing data were imputed using multiple imputation within treatment group.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares (LS) mean from ANCOVA pattern mixture model adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"bottom\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">26-Week Primary Time Point</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">TRULICITY<br/>0.75 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">TRULICITY<br/>1.5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Insulin Glargine</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Intent-to-Treat Population (N)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">190</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">192</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">194</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">8.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-0.9</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.0</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-1.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from insulin glargine<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.0 (-0.2, 0.3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">-0.1 (-0.3, 0.2)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Percentage of patients HbA1c &lt;8.0%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">73</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">75</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">74</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Fasting Serum Glucose (mg/dL) (Mean)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Baseline</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">167</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">161</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">170</td></tr><tr><td align=\\\"left\\\" class=\\\"Lrule Rrule\\\" valign=\\\"middle\\\">Change from baseline<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">6</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">14</td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\">-23</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Difference from insulin glargine<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">30 (16, 43)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">37 (24, 50)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"></td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s89\\\"></a><a name=\\\"section-13.5\\\"></a><p></p><h2>14.5 Cardiovascular Outcomes Trial in Adults with Type 2 Diabetes Mellitus and Cardiovascular Disease or Multiple Cardiovascular Risk Factors</h2><p class=\\\"First\\\">The REWIND trial (NCT01394952) was a multi-national, multi-center, randomized, placebo-controlled, double-blind trial. In this trial, 9901 adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. The median follow-up duration was 5.4 years. The primary endpoint was the time to the first occurrence of a composite 3-component Major Adverse Cardiovascular Events (MACE) outcome, which included CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.</p><p>Patients eligible to enter the trial were 50 years of age or older who had type 2 diabetes mellitus, had an HbA1c value ≤9.5% with no lower limit at screening, and had either established CV disease, or did not have established CV disease but had multiple CV risk factors. Patients who were confirmed to have established CV disease (31.5% of randomized patients) had a history of at least one of the following: MI (16.2%); myocardial ischemia by a stress test or with cardiac imaging (9.3%); ischemic stroke (5.3%); coronary, carotid, or peripheral artery revascularization (18.0%); unstable angina (5.9%); or hospitalization for unstable angina with at least one of the following: ECG changes, myocardial ischemia on imaging, or a need for percutaneous coronary intervention (12.0%). Patients confirmed to be without established CV disease, but with multiple CV risk factors, comprised 62.8% of the randomized trial population.</p><p>At baseline, demographic and disease characteristics were balanced between treatment groups. Patients had a mean age of 66 years; 46% were female; race: White, Black, and Asian were 76%, 7%, and 4%, respectively.</p><p>The median baseline HbA1c was 7.2%. The mean duration of type 2 diabetes was 10.5 years and the mean BMI was 32.3 kg/m<span class=\\\"Sup\\\">2</span>.</p><p>At baseline, 50.5% of patients had mild renal impairment (eGFR ≥60 but &lt;90 mL/min/1.73m<span class=\\\"Sup\\\">2</span>), 21.6% had moderate renal impairment (eGFR ≥30 but &lt;60 mL/min/1.73m<span class=\\\"Sup\\\">2</span>), and 1.1% of patients had severe renal impairment (eGFR &lt;30 mL/min/1.73m<span class=\\\"Sup\\\">2</span>) out of 9713 patients whose eGFR were available.</p><p>At baseline, 94.7% of patients were taking antidiabetic medication, with 10.5% of patients taking three or more antidiabetic drugs. The most common background antidiabetic drugs used at baseline were metformin (81.2%), sulfonylurea (46.0%), and insulin (23.9%). At baseline, CV disease and risk factors were managed with ACE inhibitors or angiotensin receptor blockers (81.5%), beta blockers (45.6%), calcium channel blockers (34.4%), diuretics (46.5%), statin therapy (66.1%), antithrombotic agents (58.7%), and aspirin (51.7%). During the trial, investigators were to modify anti-diabetic and cardiovascular medications to achieve local standard of care treatment targets with respect to blood glucose, lipids, and blood pressure, and manage patients recovering from an acute coronary syndrome or stroke event per local treatment guidelines.</p><p>For the primary analysis, a Cox proportional hazards model was used to test for superiority. Type I error was controlled across multiple tests. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (HR: 0.88, 95% CI 0.79, 0.99). Refer to <a href=\\\"#f06\\\">Figure 6</a> and <a href=\\\"#t14\\\">Table 14</a>.</p><p>Vital status was available for 99.7% of patients in the trial. A total of 1128 deaths were recorded during the REWIND trial. A majority of the deaths in the trial were adjudicated as CV deaths, and non-CV deaths were comparable between the treatment groups (4.4% in patients treated with TRULICITY and 5.0% in patients treated with placebo). There were 536 all-cause deaths (10.8%) in the dulaglutide group compared to 592 deaths (12.0%) in the placebo group.</p><div class=\\\"Figure\\\"><a name=\\\"f06\\\"></a><img alt=\\\"Figure 6\\n\\\" src=\\\"trulicity-pi-f6-v2.jpg\\\"/></div><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"11.100%\\\"/><col align=\\\"left\\\" width=\\\"7.867%\\\"/><col align=\\\"left\\\" width=\\\"16.389%\\\"/><col align=\\\"left\\\" width=\\\"8.233%\\\"/><col align=\\\"left\\\" width=\\\"16.744%\\\"/><col align=\\\"left\\\" width=\\\"7.756%\\\"/><col align=\\\"left\\\" width=\\\"15.544%\\\"/><col align=\\\"left\\\" width=\\\"11.456%\\\"/><col align=\\\"left\\\" width=\\\"4.911%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"9\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of patients at risk</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\">Placebo</td><td align=\\\"center\\\" valign=\\\"top\\\">4952</td><td align=\\\"center\\\" valign=\\\"top\\\">4791</td><td align=\\\"center\\\" valign=\\\"top\\\">4625</td><td align=\\\"center\\\" valign=\\\"top\\\">4437</td><td align=\\\"center\\\" valign=\\\"top\\\">4275</td><td align=\\\"center\\\" valign=\\\"top\\\">3575</td><td align=\\\"center\\\" valign=\\\"top\\\">742</td><td align=\\\"center\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\">Dulaglutide</td><td align=\\\"center\\\" valign=\\\"top\\\">4949</td><td align=\\\"center\\\" valign=\\\"top\\\">4815</td><td align=\\\"center\\\" valign=\\\"top\\\">4670</td><td align=\\\"center\\\" valign=\\\"top\\\">4521</td><td align=\\\"center\\\" valign=\\\"top\\\">4369</td><td align=\\\"center\\\" valign=\\\"top\\\">3686</td><td align=\\\"center\\\" valign=\\\"top\\\">741</td><td align=\\\"center\\\" valign=\\\"top\\\"></td></tr></tbody></table><p class=\\\"MultiMediaCaption\\\"><span class=\\\"Bold\\\">Figure 6. KAPLAN MEIER CURVE: Time to First Occurrence of MACE in the REWIND Trial</span></p><a name=\\\"t14\\\"></a><table width=\\\"100%\\\"><caption><span>Table 14: Treatment Effect for MACE and the Individual Components in the REWIND Trial, Median Trial Observation Time of 5.4 years in Adult Patients with Type 2 Diabetes Mellitus<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"40.485%\\\"/><col align=\\\"left\\\" width=\\\"19.855%\\\"/><col align=\\\"left\\\" width=\\\"19.855%\\\"/><col align=\\\"left\\\" width=\\\"19.805%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> All randomized patients.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Cox-proportional hazards model with treatment as a factor. Type I error was controlled for the primary and secondary endpoints.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> p=0.026 for superiority (2-sided).</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Number and percentage of patients with events.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">e</span> Results for components of MACE, fatal and non-fatal stroke, and fatal and non-fatal MI are listed descriptively for supportive purposes. No statistical significance should be inferred since these CIs are not adjusted for multiplicity.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Time to First Occurrence of:</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">TRULICITY</span><br/><span class=\\\"Bold\\\">N=4949</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">N=4952</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Hazard Ratio</span><br/><span class=\\\"Bold\\\">(95% CI)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death (MACE)<span class=\\\"Sup\\\">d</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">594 (12.0%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">663 (13.4%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.88 (0.79, 0.99)<span class=\\\"Sup\\\">c</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Cardiovascular death<span class=\\\"Sup\\\">d,e</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">317 (6.4%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">346 (7.0%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.91 (0.78, 1.06)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Non-fatal myocardial infarction<span class=\\\"Sup\\\">d,e</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">205 (4.1%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">212 (4.3%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.96 (0.79, 1.16)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Non-fatal stroke<span class=\\\"Sup\\\">d,e</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">135 (2.7%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">175 (3.5%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.76 (0.61, 0.95)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Fatal or non-fatal myocardial infarction<span class=\\\"Sup\\\">d,e</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">223 (4.5%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">231 (4.7%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.96 (0.79, 1.15)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Fatal or non-fatal stroke<span class=\\\"Sup\\\">d,e</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">158 (3.2%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">205 (4.1%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.76 (0.62, 0.94)</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s90\\\"></a><a name=\\\"section-13.6\\\"></a><p></p><h2>14.6 Glycemic Control Trial in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus</h2><p class=\\\"First\\\">In this 26-week randomized, double-blind, placebo-controlled, parallel-arm, multicenter trial with an open-label extension for an additional 26 weeks,154 pediatric patients 10 years of age and older with type 2 diabetes mellitus, who had inadequate glycemic control despite diet and exercise, were randomized to subcutaneous TRULICITY once weekly (0.75 mg and 1.5 mg) or subcutaneous placebo once weekly in combination with or without metformin and/or basal insulin treatment (NCT02963766).</p><p>Overall, in this trial demographic and baseline disease characteristics were comparable across the treatment groups. At baseline, 71% of patients were female, and the mean age was 14.5 years (ranging from 10 to 17 years). Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race.  Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity.  At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m<span class=\\\"Sup\\\">2</span>.</p><p>In this trial, once weekly TRULICITY (0.75 mg and 1.5 mg, pooled) (with or without metformin and/or basal insulin) was superior to placebo (p&lt;0.001) in the change from baseline at Week 26 in HbA1c in pediatric patients 10 years of age and older with type 2 diabetes mellitus (see <a href=\\\"#t15\\\">Table 15</a>).</p><a name=\\\"t15\\\"></a><table width=\\\"100%\\\"><caption><span>Table 15: Glycemic Results at Week 26 in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus with Inadequate Glycemic Control Despite Diet and Exercise (With or Without Metformin and/or Basal Insulin)</span></caption><col align=\\\"left\\\" width=\\\"33.980%\\\"/><col align=\\\"left\\\" width=\\\"11.700%\\\"/><col align=\\\"left\\\" width=\\\"19.220%\\\"/><col align=\\\"left\\\" width=\\\"18.660%\\\"/><col align=\\\"left\\\" width=\\\"16.440%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Combined results for TRULICITY 0.75 mg and 1.5 mg. The comparison of the two dosages together and individually with placebo was prespecified with overall type I error controlled.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> The change from baseline and difference from placebo were analyzed using analysis of covariance with effects for treatment, the baseline value as a covariate, and stratification factors which were HbA1c at screening (&lt; 8% vs &gt;= 8%), insulin use at baseline (yes/no), metformin use at baseline (yes/no).</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> For HbA1c and Fasting Blood Glucose, multiple imputation was performed for missing data guided by washout method. At Week 26 primary efficacy (HbA1c) was missing for 8%, 6%, and 10% of patients on placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg respectively.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> For percentage of patients HbA1c &lt; 7%, missing data was imputed as not achieving the target.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 0.75 mg once weekly</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY 1.5 mg once weekly</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TRULICITY once weekly</span><br/><span class=\\\"Bold\\\">Pooled</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Intent-to-Treat Population (N)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">51</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">51</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">52</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">103</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">HbA1c (%) (Mean)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Baseline<br/>Change from baseline at Week 26<span class=\\\"Sup\\\">b</span><br/>Difference from placebo (95% CI)<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.1<br/>0.6<br/>-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.9<br/>-0.6<br/>-1.2 (-1.8, -0.6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.2<br/>-0.9<br/>-1.5 (-2.1, -0.9)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.0<br/>-0.8<br/>-1.4 (-1.9, -0.8)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Percentage of Patients with HbA1c &lt;7.0% at Week 26</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">d</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">55%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">48%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">52%</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Fasting Blood Glucose (mg/dL) (Mean)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Baseline<br/>Change from baseline at Week 26<span class=\\\"Sup\\\">b</span><br/>Difference from placebo (95% CI)<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">159<br/>17.1<br/>-</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">149<br/>-12.8<br/>-29.9 (-50.7, -9.1)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">163<br/>-24.9<br/>-42.0 (-63.0, -20.9)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">156<br/>-18.9<br/>-35.9 (-54.2, -17.6)</td></tr></tbody></table></div></section>\",\n            \"howSupplied\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34069-5\\\"><a name=\\\"s92\\\"></a><a name=\\\"section-14.1\\\"></a><p></p><h2>16.1 How Supplied</h2><p class=\\\"First\\\">TRULICITY (dulaglutide) injection is a clear and colorless solution supplied in single-dose pens. TRULICITY is packaged in a cardboard outer carton containing 4 single-dose TRULICITY pens and is supplied as follows:</p><table width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"55.450%\\\"/><col align=\\\"left\\\" width=\\\"44.550%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Total Strength per Total Volume</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">NDC</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">0.75 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">NDC 0002-1433-80</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">1.5 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">NDC 0002-1434-80</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">3 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">NDC 0002-2236-80</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">4.5 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">NDC 0002-3182-80</td></tr></tbody></table></section>\",\n            \"useInSpecificPopulations\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43684-0\\\"><a name=\\\"s40\\\"></a><a name=\\\"section-8\\\"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42228-7\\\"><a name=\\\"s41\\\"></a><a name=\\\"section-8.1\\\"></a><p></p><h2>8.1 Pregnancy</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s42\\\"></a><a name=\\\"section-8.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Risk Summary</span></p><p>Limited data with TRULICITY in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage. There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy <span class=\\\"Italics\\\">[see Clinical Considerations].</span> Based on animal reproduction studies, there may be risks to the fetus from exposure to dulaglutide during pregnancy. TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>In pregnant rats administered dulaglutide during organogenesis, early embryonic deaths, fetal growth reductions, and fetal abnormalities occurred at systemic exposures at least 6-times human exposure at the maximum recommended human dose (MRHD) of 4.5 mg/week. In pregnant rabbits administered dulaglutide during organogenesis, major fetal abnormalities occurred at 5-times human exposure at the MRHD. Adverse embryo/fetal effects in animals occurred in association with decreased maternal weight and food consumption attributed to the pharmacology of dulaglutide <span class=\\\"Italics\\\">[see Data]</span>.</p><p>The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c &gt;7% and has been reported to be as high as 20–25% in women with an HbA1c &gt;10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s43\\\"></a><a name=\\\"section-8.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Considerations</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s44\\\"></a><a name=\\\"section-8.1.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Disease-associated maternal and/or embryo/fetal risk</span></p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s45\\\"></a><a name=\\\"section-8.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Data</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s46\\\"></a><a name=\\\"section-8.1.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Animal Data</span></p><p>Pregnant rats given subcutaneous doses of 0.49, 1.63, or 4.89 mg/kg dulaglutide every 3 days during organogenesis had systemic exposures 2-, 6-, and 18-times human exposure at the maximum recommended human dose (MRHD) of 4.5 mg/week, respectively, based on plasma area under the time-concentration curve (AUC) comparison. Reduced fetal weights associated with decreased maternal food intake and decreased weight gain attributed to the pharmacology of dulaglutide were observed at ≥1.63 mg/kg. Irregular skeletal ossifications and increases in post-implantation loss also were observed at 4.89 mg/kg.</p><p>In pregnant rabbits given subcutaneous doses of 0.04, 0.12, or 0.41 mg/kg dulaglutide every 3 days during organogenesis, systemic exposures in pregnant rabbits were 0.5-, 2-, and 5-times human exposure at the MRHD, based on plasma AUC comparison. Fetal visceral malformation of lung lobular agenesis and skeletal malformation"